Decoy Therapeutics holds special shareholder meeting with quorum present

• Shareholders met on Sept. 14, 2026 to vote on two capital structure items.
• Backed issuing common stock upon exercise of Series A, Series B, Series C common warrants from a private placement.
• Adopted a charter amendment to cut authorized common shares by 10 million to 90 million; the filing does not confirm execution.
• An adjournment item was not taken up because the other measures passed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001615219-26-000016), on September 15, 2026, and is solely responsible for the information contained therein.